Anti-Daratumumab antibody

Description:

Anti-Daratumumab is a chimeric rabbit/human anti-idiotypic antibody specifically designed to target the human therapeutic antibody Daratumumab. This recombinant antibody is composed of rabbit variable domains and human constant domains, and it primarily binds to free Daratumumab in samples.

Target:

Daratumumab is a human IgG1/kappa antibody that recognizes CD38 molecules. CD38 is expressed in various human tissues, with the highest expression in hematopoietic tissues, particularly on plasma cells.

The Anti-Daratumumab antibody has been evaluated in ELISA. Users are advised to validate other techniques. It is recommended to test Anti-Daratumumab by titrating the product in the chosen technique, using appropriate negative and positive controls.

For further information or technical support, please contact us.

For research use only!

Find out more information about the scientific background of the product.

1. Piedra-Quintero ZL, Wilson Z, Nava P, Guerau-de-Arellano M. CD38: An Immunomodulatory
   Molecule in Inflammation and Autoimmunity. Front Immunol. 2020; 11. PMID:33329591.
2. European Medicines Agency (EMA). Darzalex (daratumumab).
   https://www.ema.europa.eu/en/medicines/human/EPAR/darzalex. 2020.
3. Großerichter-Wagener C, Kos D, van Leeuwen A, Dijk L, Jeremiasse J, Loeff FC et al. Biased
   anti-idiotype response in rabbits leads to high-affinity monoclonal antibodies to biologics.
   MAbs 2020; 12. PMID:32887534.

Fill in the information below.